Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced the presentation of interim analysis results from a Phase Ib clinical study for its investigational drug M701 at the 2024 European Society of Medical Oncology (ESMO) Congress. M701 is a recombinant anti-EpCAM and CD3 human murine chimeric bispecific antibody (BsAb) injection designed for patients with malignant pleural effusion caused by non-small cell lung cancer (NSCLC).
The drug candidate M701 is engineered to activate immune cells while simultaneously inhibiting tumor cell growth within the chest cavity, effectively inhibiting the development of pleural effusion. M701 is currently under investigation in multiple clinical studies in China, focusing on malignant ascites and malignant pleural effusion, including a pivotal Phase III study for malignant ascites caused by epithelial solid tumors.- Flcube.com
